Ovarian Endometrioid Adenocarcinoma Recruiting Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0028505 (Ovarian Endometrioid Adenocarcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03587311Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTreatment
NCT03648489Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)Treatment